Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed in Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer
NCT04761185Phase 1Completed
- Sponsor
- Fudan University
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of raltitrexed in colorectal cancer (CRC), sponsored by Fudan University. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Sep 2020; status: completed.
02
Drugs
raltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04761185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761185.